United States· US:59651-159_220fd0f3-2953-429f-bcfd-223bff2e25ce
Dapagliflozin
A dapagliflozin product containing dapagliflozin, registered in United States by Aurobindo Pharma Limited. The same ATC class is registered in 16 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Dapagliflozin is registered in 16 of 19 countries.
Countries holding a registration under ATC A10BK01 (dapagliflozin), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Dapagliflozin · ATC A10BK01
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of dapagliflozin costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $0.33 in United States to $4.38 in Switzerland — a ×13 gap.
- United States: $0.33 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Dapagliflozin · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$4.38
- IT Italy$3.42
- US United States$0.33 (acquisition cost)
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DAPAGLIFLOZIN
- Manufacturer
- Aurobindo Pharma Limited
- Country
- United States (US)
- ATC code
- A10BK01
- ATC class
- Dapagliflozin
- Defined daily dose
- 10 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1159651-159-30
- ndc1159651-159-90
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
426 interactions on record for dapagliflozin.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dapagliflozin · interactions on record
426 records
- 1 severe
- 378 moderate
- 47 minor
Most severe, free to view
- SucralfateA02BX02moderate
- PapaverineA03AD01moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Dapagliflozin in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaDAPAGLIFLOZIN AVIANTAAvianta Pharma EU Limited, Dublin
- PolandDaforbisViatris Ltd
- SpainDAFORBIS 5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGViatris Limited
- NetherlandsDapagliflozine Accord 5 mg filmomhulde tablettenAccord Healthcare B.V.
- SwedenDaforbis 5 mg Filmdragerad tablettViatris Limited
- SwitzerlandDapagliflozin Devatis 5 mg, FilmtablettenDevatis AG
- IcelandDapagliflozin KrkaKrka, d.d., Novo mesto
- IrelandDapagliflozin MSN 5 mg film-coated tabletsMSN Labs Europe Limited
Authorised across Europe · EMA
The same active substance is authorised in 31 EEA countries. Names it is sold under:
- Austria · Dapagliflozin +pharma, Dapagliflozin Devatis
- Belgium · Dapagliflozin Ab, Dapagliflozin Eg
- Bulgaria · Dapagliflozin Sandoz, Dapagliflozin Tchaikapharma
- Cyprus · Daforbis, Dapagliflozin Farmoz
- Czechia · Dagetia, Dagrafors
- Germany · Daglin, Dapagliflozin 123-Acurae Pharma
- Denmark · Dapagliflozin, Dapagliflozin "sandoz"
- Estonia · Dagrafors, Dapagliflozin Alembic
- Spain · Daforbis, Dapagliflozina Aurovitas
- Finland · Dapagliflozin Devatis, Dapagliflozin Krka
- France · Dapagliflozine Arrow, Dapagliflozine Biogaran
- United Kingdom (Northern Ireland) · Daforbis, Dapagliflozin
- Greece · Brolertix, Daforbis
- Croatia · Daforbis, Dagrafors
- Hungary · Dagrafors, Dapagliflozin Sandoz
- Ireland · Dapagliflozin Clonmel, Dapagliflozin Krka
- Iceland · Dapagliflozin Krka, Dapagliflozin Krka D.D.
- Italy · Dapagliflozin Aurobindo, Dapagliflozin Doc
- Liechtenstein · Dapagliflozin Viatris, Edistride
- Lithuania · Dagrafors, Dapagliflozin Accord
- Luxembourg · Dapagliflozin Eg
- Latvia · Daglin, Dagrafors
- Malta · Dapagliflozin Ascend, Dapagliflozin Aurobindo
- Netherlands · Dapagliflozin Alembic, Dapagliflozin Amarox
- Norway · Dapagliflozin Alembic, Dapagliflozin Devatis
- Poland · Daforbis, Dagrafors
- Portugal · Dalzior, Dapagliflozin Ipca
- Romania · Daforbis, Dagetia
- Sweden · Daforbis, Dapagliflozin Adalvo
- Slovenia · Dagrafors, Dapagliflozin Hcs
- Slovakia · Dagetia, Dagrafors
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f78e69f4-18e8-49bc-ab65-13078773c4d7 GET /v1/drugs/f78e69f4-18e8-49bc-ab65-13078773c4d7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "5",
"substance": "DAPAGLIFLOZIN",
"productndc": "59651-159",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA211468",
"marketing_category": "ANDA"
}See everything about dapagliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.